Table 1.

Alterations in the expression of AIM2 in human cancers

Cancer type	Alteration	Phenotype/clinical outcome
Cervical cancer (CC)	Overexpression due to hypomethylation of AIM2	Not known [23]
HNPCC-associated small bowl cancer (SBC)	Loss of expression (frame-shift mutation)	Poor prognosis [27]
Colorectal cancer	Loss of expression (microsatellite instability)	Poor prognosis [29, 30]
Nasopharyngeal carcinoma (NPC)	Overexpression	Correlated with survival [31]
Oral squamous cell carcinoma (OSCC)	Overexpression	p53-dependent inhibition [32]
Non-small cell lung cancer (NSCLC)	Overexpression	Poor prognosis [33]
Oral cancer	Overexpression	Not known [34]
Cervical cancer	Overexpression (amplification of 1q22–23 region)	Not known [75]